Posted by Michael Wonder on 07 Dec 2023
Dupilumab for the treatment of patients with eosinophilic oesophagitis
7 December 2023 - NICE is unable to make a recommendation on the use of dupilumab (Dupixent) for the treatment of patients 12 years and older with eosinophilic oesophagitis because Sanofi did not provide an evidence submission.
NICE will review this decision if Sanofi decides to make a submission.
